Forte Biosciences (FBRX) Cash & Equivalents (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Cash & Equivalents data on file, last reported at $58.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 26.92% year-over-year to $58.2 million in Q1 2026; TTM through Mar 2026 was $58.2 million, a 26.92% increase from a year earlier, with the FY2025 full-year figure at $77.0 million, up 245.97% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $58.2 million, down from $77.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for FBRX reached as high as $106.1 million in Q2 2025 and fell as low as $16.4 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $45.7 million across 5 years, with a median of $40.0 million in 2022.
• Across the five-year window, Cash & Equivalents tumbled 64.49% in 2024 and jumped 469.51% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $41.1 million in 2022, then declined by 9.67% to $37.1 million in 2023, then plunged by 40.08% to $22.2 million in 2024, then surged by 245.97% to $77.0 million in 2025, then slipped by 24.37% to $58.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $58.2 million in Q1 2026, $77.0 million in Q4 2025, and $93.4 million in Q3 2025.